SUBSCRIBE
SUBSCRIBE

ALX Oncology

NEWS
Business
BioSpace Movers & Shakers, May 8
Pharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
May 7, 2020
 · 
5 min read
 · 
Alex Keown
Load More
JOBS
IN THE PRESS
Press Releases
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 1, 2026
 · 
15 min read
Press Releases
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
February 19, 2026
 · 
2 min read
Press Releases
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
February 19, 2026
 · 
1 min read
Press Releases
ALX Oncology Announces Pricing of Underwritten Offering - January 30, 2026
February 1, 2026
 · 
4 min read
Press Releases
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
February 1, 2026
 · 
4 min read
Press Releases
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 9, 2026
 · 
1 min read
Press Releases
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
January 9, 2026
 · 
5 min read
Press Releases
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
December 8, 2025
 · 
5 min read
Press Releases
ALX Oncology to Present at Upcoming Investor Conferences
November 19, 2025
 · 
1 min read
Press Releases
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 10, 2025
 · 
14 min read
Load More